About WUXI BIO Company

The Group is a world-leading open-access biopharmaceutical CRDMO, offering end-to-end solutions for the discovery, development, and manufacturing of biologics. Biologics represent a specialized subcategory of pharmaceuticals that have revolutionized treatment approaches across many major therapeutic areas worldwide. The Group's comprehensive end-to-end CRDMO service platform enables it to provide services spanning the entire biologic development lifecycle and to deliver customized solutions at any stage of the process, tailored to each client's specific needs. The biologic development process typically comprises five phases: (i) drug discovery; (ii) preclinical development; (iii) early-phase (Phase I and Phase II) clinical development; (iv) late-phase (Phase III) clinical development; and (v) commercial-scale manufacturing. The services required throughout the biologic development process can be broadly categorized into two types: (1) pre-IND services, which encompass offerings provided during the first two phases of development, and (2) post-IND services, which cover the remaining three phases. The Group's business model is underpinned by its "Follow and Win the Molecule" strategy. Client demand for the Group's services generally increases as their biologics advance through the development pipeline and ultimately reach commercial production. Consequently, revenue per integrated project typically grows in tandem with project progress.